In vivo experiments further confirmed that ZKSCAN3-shRNA-treated bladder cancer cells had significantly diminished tumorigenicity in a xenograft mouse model, as evidenced by a reduction in tumor size and malignancy [54,87]. The gene discussed is ZKSCAN3; the disease is urinary bladder carcinoma.